ETPrime

Natco Pharma Share Price

  • 826.204.36 (0.53%)
  • Volume: 9,01,682
  • Closed
  • Last Updated On: 17 Oct, 2025, 03:54 PM IST
High: "1200.00",Open: "946.56",Low: "712.00",
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Loading...
Natco Pharma Share Price
  • 826.204.36 (0.53%)
  • Volume: 9,01,682
Advertisment
Stock Recommendations

  • Potential
    Upside

  • 1 Year
    Target

HOLD

Mean Recos by
9 Analysts

2

2

2

1

2

Strong Sell

Sell

Hold

Buy

Strong Buy

Unlock Potential Upside
Stock Reports Plus

/10

Stock Score

View Report
Earnings
Fundamentals
Relative Valuation
Risk
Price Momentum
No Rating (NR)
Negative
Neutral
Positive
Unlock Stock Score

Key Metrics

PE Ratio
(x)		8.72
EPS - TTM
(₹)		94.78
MCap
(₹ Cr.)		14,798.06
Sectoral MCap Rank
35
PB Ratio
(x)		1.93
Div Yield
(%)		0.73
Face Value
(₹)		2.00
Beta

Beta

1 Month0.45
3 Months0.54
6 Months0.38
1 Year0.70
3 Years0.78

0.45
VWAP
(₹)		832.44
52W H/L
(₹)
1,505.00 / 726.80

Natco Pharma share price insights

View All

  • Company delivered ROE of 24.78% in year ending Mar 31, 2025 outperforming its 5 year avg. of 17.22%. (Source: Consolidated Financials)

  • Company has spent less than 1% of its operating revenues towards interest expenses and 13.42% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

  • 14 day moving crossover appeared on Oct 17, 2025. Average price gain of 4.05% within 7 days of this signal in last 5 years.

  • 10 day moving crossover appeared on Oct 17, 2025. Average price gain of 4.01% within 7 days of this signal in last 5 years.

  • Natco Pharma Ltd. share price moved up by 0.53% from its previous close of Rs 821.85. Natco Pharma Ltd. stock last traded price is 826.20

    Share PriceValue
    Today/Current/Last826.20
    Previous Day821.85821.75

InsightsNatco Pharma

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Natco Pharma Share Price Returns

    1 Day0.53%
    1 Week-2.32%
    1 Month-3.62%
    3 Months-20.0%
    1 Year-40.53%
    3 Years38.79%
    5 Years-7.24%

    ET Stock ScreenersTop Score Companies

    Check whether Natco Pharma belongs to analysts' top-rated companies list?

    View Stock Screeners

    Natco Pharma News & Analysis

    View all Natco Pharma Share News & Announcements

    Natco Pharma Share Recommendations

    Recent Recos

    HOLD

    Current

    Mean Recos by 9 Analysts

    Strong
    Sell    SellHoldBuyStrong
    Buy
    • Target₹1145
    • OrganizationICICI Securities
    • ADD
    • Target₹1116
    • OrganizationGeojit Financial Services
    • BUY

    Analyst Trends

    RatingsCurrent1 Week Ago1 Month Ago3 Months Ago
    Strong Buy2221
    Buy1111
    Hold2222
    Sell2222
    Strong Sell222-
    # Analysts9996
    View all Stock Recommendations

    Natco Pharma Financials

    • Insights

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.42% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income1,390.601,287.30651.101,434.901,410.70
      Total Income Growth (%)8.0297.71-54.621.7227.06
      Total Expenses815.50771.20483.00612.60601.90
      Total Expenses Growth (%)5.7459.67-21.161.78-3.93
      EBIT575.10516.10168.10822.30808.80
      EBIT Growth (%)11.43207.02-79.561.6767.18
      Profit after Tax (PAT)480.70406.60133.00677.30668.50
      PAT Growth (%)18.22205.71-80.361.3273.05
      EBIT Margin (%)41.3640.0925.8257.3157.33
      Net Profit Margin (%)34.5731.5920.4347.2047.39
      Basic EPS (₹)26.8422.707.4337.8137.32
      Quarterly | AnnualJun 2025Mar 2025Dec 2024Sep 2024Jun 2024
      Total Income1,252.301,219.50575.601,344.001,276.70
      Total Income Growth (%)2.69111.87-57.175.2727.58
      Total Expenses706.80689.90421.90544.10514.30
      Total Expenses Growth (%)2.4563.52-22.465.79-8.76
      EBIT545.50529.60153.70799.90762.40
      EBIT Growth (%)3.00244.57-80.794.9274.46
      Profit after Tax (PAT)464.10428.10124.90661.10636.30
      PAT Growth (%)8.41242.75-81.113.9082.27
      EBIT Margin (%)43.5643.4326.7059.5259.72
      Net Profit Margin (%)37.0635.1021.7049.1949.84
      Basic EPS (₹)25.9123.906.9736.9135.53
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue4,784.004,126.902,811.702,043.802,155.70
      Total Revenue Growth (%)15.9246.7837.57-5.196.59
      Total Expenses2,492.602,453.401,949.801,841.601,576.10
      Total Expenses Growth (%)1.6025.835.8816.858.42
      Profit after Tax (PAT)1,885.401,388.30715.30170.00440.90
      PAT Growth (%)35.8194.09320.76-61.44-4.32
      Operating Profit Margin (%)52.2742.3332.3711.3028.89
      Net Profit Margin (%)42.5634.7126.428.7421.48
      Basic EPS (₹)105.2677.3439.189.3224.20
      Quarterly | Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Revenue4,415.803,673.602,436.501,862.401,754.60
      Total Revenue Growth (%)20.2050.7730.836.14-8.33
      Total Expenses2,189.802,118.301,665.801,706.501,362.40
      Total Expenses Growth (%)3.3827.16-2.3825.262.37
      Profit after Tax (PAT)1,850.401,306.60637.10139.10309.50
      PAT Growth (%)41.62105.09358.02-55.06-34.77
      Operating Profit Margin (%)54.8443.9833.149.5724.40
      Net Profit Margin (%)45.1936.6127.097.8618.71
      Basic EPS (₹)103.3172.7934.907.6316.99

      All figures in Rs Cr, unless mentioned otherwise

      View Details
    • Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets8,630.806,906.305,657.405,109.104,791.90
      Total Assets Growth (%)24.9722.0810.736.624.45
      Total Liabilities1,018.501,053.20783.60845.50668.50
      Total Liabilities Growth (%)-3.2934.41-7.3226.48-16.76
      Total Equity7,612.305,853.104,873.804,263.604,123.40
      Total Equity Growth (%)30.0620.0914.313.408.95
      Current Ratio (x)5.594.144.393.524.45
      Total Debt to Equity (x)0.040.060.030.090.06
      Contingent Liabilities50.7058.8022.1022.4028.00
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Total Assets8,269.906,554.005,387.904,978.004,752.50
      Total Assets Growth (%)26.1821.648.234.742.28
      Total Liabilities936.00961.70685.90786.10661.40
      Total Liabilities Growth (%)-2.6740.21-12.7518.85-14.90
      Total Equity7,333.905,592.304,702.004,191.904,091.10
      Total Equity Growth (%)31.1418.9312.172.465.73
      Current Ratio (x)5.423.854.383.344.17
      Total Debt to Equity (x)0.040.060.030.090.06
      Contingent Liabilities50.7058.8055.0052.3042.80

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • Increase in Cash from Investing

        Company has used Rs 1414.5 cr for investing activities which is an YoY increase of 36.97%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,696.801,211.60849.1046.50298.80
      Net Cash used in Investing Activities-1,414.50-1,032.70-477.10-5.30-103.30
      Net Cash flow from Financing Activities-210.70-246.90-363.0034.80-185.70
      Net Cash Flow49.60-61.5020.8085.306.00
      Closing Cash & Cash Equivalent120.0070.40131.90111.1025.80
      Closing Cash & Cash Equivalent Growth (%)70.45-46.6318.72330.6230.30
      Total Debt/ CFO (x)0.160.300.198.690.89
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Net Cash flow from Operating Activities1,662.001,196.40784.4057.70183.50
      Net Cash used in Investing Activities-1,443.90-960.50-436.60-92.50-3.20
      Net Cash flow from Financing Activities-212.40-237.30-346.8035.60-183.10
      Net Cash Flow5.70-1.401.000.80-2.80
      Closing Cash & Cash Equivalent11.205.506.905.905.10
      Closing Cash & Cash Equivalent Growth (%)103.64-20.2916.9515.69-35.44
      Total Debt/ CFO (x)0.160.300.206.741.39

      All figures in Rs Cr, unless mentioned otherwise

      View Details

    • Insights

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 24.78% in year ending Mar 31, 2025 outperforming its 5 year avg. of 17.22%. (Source: Consolidated Financials)
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)24.7823.7114.673.9810.69
      Return on Capital Employed (%)30.1128.5217.614.9913.89
      Return on Assets (%)21.8420.1012.643.329.20
      Interest Coverage Ratio (x)106.7297.8971.7420.4853.37
      Asset Turnover Ratio (x)0.570.640.500.360.35
      Price to Earnings (x)7.5812.2714.3981.3034.25
      Price to Book (x)1.882.912.113.243.65
      EV/EBITDA (x)4.858.759.5238.6721.19
      EBITDA Margin (%)57.5747.0038.4218.6334.58
      Annual FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
      Return on Equity (%)25.2323.3613.543.317.56
      Return on Capital Employed (%)30.3227.6916.173.919.52
      Return on Assets (%)22.3719.9311.822.796.51
      Interest Coverage Ratio (x)125.80120.12108.1623.1345.90
      Asset Turnover Ratio (x)0.550.600.450.360.35
      Price to Earnings (x)7.7213.0416.16100.0048.78
      Price to Book (x)1.953.052.193.303.68
      EV/EBITDA (x)5.159.4910.7945.8729.02
      EBITDA Margin (%)60.2148.8039.5617.4031.36

    Financial InsightsNatco Pharma

    • Income (P&L)
    • Cash Flow
    • Ratios

      • Employee & Interest Expense

        Company has spent less than 1% of its operating revenues towards interest expenses and 13.42% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

      • Increase in Cash from Investing

        Company has used Rs 1414.5 cr for investing activities which is an YoY increase of 36.97%. (Source: Consolidated Financials)

      • ROE Outperforming 5 Year Average

        Company delivered ROE of 24.78% in year ending Mar 31, 2025 outperforming its 5 year avg. of 17.22%. (Source: Consolidated Financials)

    Do you find these insights useful?

    • hate it

    • meh

    • love it

    Natco Pharma Share Price Forecast

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    • Get multiple analysts’ prediction on Natco Pharma

      Stock Forecast Non Prime User
      • High, low, medium predictions for Price
      • Upcoming predictions for Revenue
      • Details about company earnings
      START FREE TRIAL

    Natco Pharma Technicals

    • Bullish / Bearish signals for Natco Pharma basis selected technical indicators and moving average crossovers.

      5 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 17 Oct 2025

      5D EMA: 823.31

      Last 4 Buy Signals:9 Oct 2025
      Date7 days Gain/Loss %
      9 Oct 20256.30%
      3 Oct 20250.91%
      17 Sep 20254.63%
      12 Sep 20250.43%

      Average price gain of 3.50% within 7 days of Bullish signal in last 5 years

      10 Day EMA Crossover

      Bullish signal on daily chart

      Appeared on: 17 Oct 2025

      10D EMA: 823.38

      Last 4 Buy Signals:10 Oct 2025
      Date7 days Gain/Loss %
      10 Oct 20250.24%
      17 Sep 20254.63%
      12 Sep 20250.43%
      14 Jul 20258.39%

      Average price gain of 3.99% within 7 days of Bullish signal in last 5 years

      Show More
    • 42%
      Positive Movement since
      1st Jan 2005 on basis
      58%
      Negative Movement since
      1st Jan 2005 on basis
      Exclude

    • Pivot Levels

      R1R2R3PIVOTS1S2S3
      Classic844.25862.30894.75829.85811.80797.40764.95

      Average True Range

      5 DAYS14 DAYS28 DAYS
      ATR22.1121.7223.22

    Natco Pharma Peer Comparison

      • CHART
      • TABLE

      • Choose from Peers

          Choose from Stocks

          • 1D
          • 1W
          • 1M
          • 3M
          • 6M
          • 1Y
          • 5Y
          Loading...

        • Ratio Performance

          NAMEP/E (x)P/B (x)ROE %ROCE %ROA %Rev CAGR [3Yr]OPMNPMBasic EPSCurrent RatioTotal Debt/ Equity (x)Total Debt/ CFO (x)
          Natco Pharma8.721.9424.7830.1121.8432.4052.2742.51105.265.590.040.16
          Neuland Labs118.5913.7017.0616.2311.9316.0718.8317.61202.742.450.090.43
          Alembic Pharma30.593.5611.2314.407.507.7411.578.7129.681.690.2313.59
          Sai Life Science Ltd.74.498.547.9912.515.3824.2017.9310.038.832.050.060.41
          Jubilant Life37.372.7613.418.136.585.8311.9111.5652.991.650.392.27
          Add More
          Annual Ratios (%)

          Choose from Peers

          • Concord Biotech Ltd.
          • Caplin Point
          • Granules India
          • Aarti Inds
          • Blue Jet Healthcare

          Choose from Stocks

            See All Parameters

          Peers InsightsNatco Pharma

            Do you find these insights useful?

            • hate it

            • meh

            • love it

            Natco Pharma Shareholding Pattern

            • Loading...
              Showing Natco Pharma Shareholding as on Sep 2025
              CategorySep 2025Jun 2025Mar 2025Dec 2024
              Promoters49.4849.5649.5649.62
              Pledge0.000.000.000.00
              FII14.0915.5217.4917.94
              DII5.875.645.475.58
              Mutual Funds2.202.111.851.92
              Others30.5629.2827.4826.86
            • Showing Shareholding as on Sep 2025
              CategoryNo. of SharesPercentage% Change QoQ
              Promoters8,86,30,12649.48 %-0.08
              Pledge00.00 %0.00
              FII2,52,34,50314.09 %-1.42
              DII1,05,09,9975.87 %0.23
              MF39,31,9472.20 %0.09
              Others5,47,35,24430.56 %1.28

            Natco Pharma MF Ownership

            MF Ownership as on 30 September 2025

            View all Mutual Fund Schemes
            Top Searches:
            Natco Pharma News Natco Pharma Quarterly Results Natco Pharma Dividend Natco Pharma Q1 ResultsNatco Pharma Q2 ResultsNatco Pharma Q3 ResultsNatco Pharma Q4 Results

            Natco Pharma Corporate Actions

            • Meeting DateAnnounced onPurposeDetails
              Sep 25, 2025Sep 01, 2025AGM-
              Aug 12, 2025Aug 04, 2025Board MeetingQuarterly Results & Interim Dividend
              May 28, 2025May 12, 2025Board MeetingAudited Results
              Feb 12, 2025Jan 30, 2025Board MeetingQuarterly Results & Interim Dividend
              Nov 12, 2024Oct 28, 2024Board MeetingQuarterly Results & Interim Dividend
            • TypeDividendDividend per ShareEx-Dividend DateAnnounced on
              Interim100%2.0Aug 19, 2025Aug 12, 2025
              Interim75%1.5Feb 18, 2025Feb 12, 2025
              Interim75%1.5Nov 27, 2024Nov 12, 2024
              Interim150%3.0Aug 23, 2024Aug 12, 2024
              Interim62%1.25Feb 26, 2024Feb 14, 2024
            • All TypesEx-DateRecord DateAnnounced onDetails
              SplitsNov 26, 2015Nov 28, 2015Aug 12, 2015Split: Old FV10.0| New FV:2.0

            About Natco Pharma

            Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,798.06 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Agrochemicals, Export Incentives, Other Operating Revenue, Scrap for the year ending 31-Mar-2025. Show More

            • Executives

            • Auditors

            • VC

              V C Nannapaneni

              Chairman & Managing Director
              RN

              Rajeev Nannapaneni

              Vice Chairman & CEO
              PS

              P S R K Prasad

              Director & Exe. VP (Corp. Engg. Services)
              AD

              A D M Chavali

              Independent Director
              Show More
            • B S R & Associates LLP

            Industry

            Pharma - Indian

            Key Indices Listed on

            Nifty Smallcap 100, Nifty 500, BSE 500, + 19 more

            Address

            NATCO House, Road # 2,Banjara Hills,Hyderabad, Telangana - 500034

            Contact

            [email protected]

            http://www.natcopharma.co.in

            More Details

            FAQs about Natco Pharma share

            • 1. What is Natco Pharma share price and what are the returns for Natco Pharma share?
              Natco Pharma share price is Rs 826.20 as on 17 Oct, 2025, 04:01 PM IST. Natco Pharma share price is up by 0.53% based on previous share price of Rs 820.25. Natco Pharma share price trend:
              • Last 12 Months: Natco Pharma share price moved down 40.53%
              • Last 3 Years: Natco Pharma Share price moved up by 38.79%
            • 2. What are the returns for Natco Pharma share?
              Return Performance of Natco Pharma Shares:
              • 1 Week: Natco Pharma share price moved down by 2.32%
              • 6 Month: Natco Pharma share price moved down by 0.17%
            • 3. What has been highest price of Natco Pharma share in last 52 weeks?
              Natco Pharma share price saw a 52 week high of Rs 1,505.00 and 52 week low of Rs 726.80.
            • 4. What is the PE & PB ratio of Natco Pharma?
              The PE ratio of Natco Pharma stands at 8.67, while the PB ratio is 1.93.
            • 5. What is the market cap of Natco Pharma?
              Natco Pharma share has a market capitalization of Rs 14,798.06 Cr. Within Pharmaceuticals sector, it's market cap rank is 35.

            Trending in Markets

            Top Gainers As on 03:59 PM | 17 Oct 2025

            Netweb Technologies3,833.10
            2026.30 (112.15%)
            HBL Power936.05
            334.85 (55.70%)
            Anand Rathi Wealth3,125.10
            1082.20 (52.97%)
            Syrma SGS Technology787.00
            258.00 (48.77%)
            Usha Martin455.30
            145.50 (46.97%)

            Top Losers As on 03:59 PM | 17 Oct 2025

            Tata Investment889.00
            -5995.00 (-87.09%)
            Adani Power165.98
            -401.17 (-70.73%)
            Patanjali Foods587.85
            -1092.15 (-65.01%)
            Godfrey Philips3,411.70
            -4767.30 (-58.29%)
            SKF India2,219.60
            -2457.00 (-52.54%)

            DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

            DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

            By using this site, you agree to the Terms of Service and Privacy Policy.

            Business News›Markets›Stocks›Stock Price Quotes›Natco Pharma Share Price
            The Economic Times
            BrowseCompanies: